Prevalence and type of KIT mutations in diagnostic specimens from 203 patients with CBF AML enrolled on 4 pediatric oncology trials
| . | No. of samples analyzed . | |||||
|---|---|---|---|---|---|---|
| Total . | WT KIT, n (%) . | KIT mutation+, n (%) . | Exon 8 mutation+, no. (%) . | Exon 17 mutation+, no. (%) . | Both exon 8/17 mutation+, no. (%) . | |
| Summation of all studies | ||||||
| All CBF AML | 203 | 165 (81) | 38 (19) | 20 (10) | 17 (8) | 1 (< 1) |
| t(8;21) | 113 | 94 (83) | 19 (17) | 6 (5) | 13 (12) | 0 (0) |
| inv(16) | 90 | 71 (79) | 19 (21) | 14 (16) | 4 (4) | 1 (1) |
| By study | ||||||
| POG-9421 | ||||||
| All CBF AML | 48 | 37 (77) | 11 (23) | 5 (10) | 6 (13) | 0 (0) |
| t(8;21) | 25 | 17 (68) | 8 (32) | 3 (12) | 5 (20) | 0 (0) |
| inv(16) | 23 | 20 (87) | 3 (13) | 2 (9) | 1 (4) | 0 (0) |
| CCG-2891 | ||||||
| All CBF AML | 18 | 13 (72) | 5 (28) | 4 (22) | 1 (6) | 0 (0) |
| t(8;21) | 8 | 7 (88) | 1 (13) | 0 (0) | 1 (13) | 0 (0) |
| inv(16) | 10 | 6 (60) | 4 (40) | 4 (40) | 0 (0) | 0 (0) |
| CCG-2961 | ||||||
| All CBF AML | 98 | 83 (85) | 15 (15) | 8 (8) | 6 (6) | 1 (1) |
| t(8;21) | 61 | 53 (87) | 8 (13) | 3 (5) | 5 (8) | 0 (0) |
| inv(16) | 37 | 30 (81) | 7 (19) | 5 (14) | 1 (3) | 1 (3) |
| COG AAML03P1 | ||||||
| All CBF AML | 39 | 32 (82) | 7 (18) | 3 (8) | 4 (10) | 0 (0) |
| t(8;21) | 19 | 17 (89) | 2 (11) | 0 (0) | 2 (11) | 0 (0) |
| inv(16) | 20 | 15 (75) | 5 (25) | 3 (15) | 2 (10) | 0 (0) |
| . | No. of samples analyzed . | |||||
|---|---|---|---|---|---|---|
| Total . | WT KIT, n (%) . | KIT mutation+, n (%) . | Exon 8 mutation+, no. (%) . | Exon 17 mutation+, no. (%) . | Both exon 8/17 mutation+, no. (%) . | |
| Summation of all studies | ||||||
| All CBF AML | 203 | 165 (81) | 38 (19) | 20 (10) | 17 (8) | 1 (< 1) |
| t(8;21) | 113 | 94 (83) | 19 (17) | 6 (5) | 13 (12) | 0 (0) |
| inv(16) | 90 | 71 (79) | 19 (21) | 14 (16) | 4 (4) | 1 (1) |
| By study | ||||||
| POG-9421 | ||||||
| All CBF AML | 48 | 37 (77) | 11 (23) | 5 (10) | 6 (13) | 0 (0) |
| t(8;21) | 25 | 17 (68) | 8 (32) | 3 (12) | 5 (20) | 0 (0) |
| inv(16) | 23 | 20 (87) | 3 (13) | 2 (9) | 1 (4) | 0 (0) |
| CCG-2891 | ||||||
| All CBF AML | 18 | 13 (72) | 5 (28) | 4 (22) | 1 (6) | 0 (0) |
| t(8;21) | 8 | 7 (88) | 1 (13) | 0 (0) | 1 (13) | 0 (0) |
| inv(16) | 10 | 6 (60) | 4 (40) | 4 (40) | 0 (0) | 0 (0) |
| CCG-2961 | ||||||
| All CBF AML | 98 | 83 (85) | 15 (15) | 8 (8) | 6 (6) | 1 (1) |
| t(8;21) | 61 | 53 (87) | 8 (13) | 3 (5) | 5 (8) | 0 (0) |
| inv(16) | 37 | 30 (81) | 7 (19) | 5 (14) | 1 (3) | 1 (3) |
| COG AAML03P1 | ||||||
| All CBF AML | 39 | 32 (82) | 7 (18) | 3 (8) | 4 (10) | 0 (0) |
| t(8;21) | 19 | 17 (89) | 2 (11) | 0 (0) | 2 (11) | 0 (0) |
| inv(16) | 20 | 15 (75) | 5 (25) | 3 (15) | 2 (10) | 0 (0) |
CBF AML indicates core binding factor acute myeloid leukemia; WT, wild-type; +, mutation positive; POG, Pediatric Oncology Group; CCG, Children's Cancer Group; and COG, Children's Oncology Group.